Phase 1 study of elotuzumab (Elo) in combination with lenalidomide/dexamethasone (Len/dex) in Japanese patients (pts) with relapsed or refractory multiple myeloma (RRMM) and long-term follow-up
この論文をさがす
説明
e162 induction chemotherapy (p>0.5) was associated to a higher rate of ER. Median OS was shorter for the ER group (19.9 months) compared to 81 months for those patients relapsing >12 months. (p1⁄40.0001) In conclusion, patients with ER after auto-SCT remain to be a challenge. Even with the advent of novel agents, patients with ER had poor outcomes. ER seems to be associated to HRC and low degree of response. Patients with these features should be considered for novel alternatives, aiming to achieve and sustain the deepest possible response. More biological insights on ER cases are needed to further improve survival outcomes. Table 1 Clinical Characteristics Characteristic N[212 Age (median) 58
収録刊行物
-
- Clinical Lymphoma Myeloma and Leukemia
-
Clinical Lymphoma Myeloma and Leukemia 15 e162-, 2015-09-01
Elsevier BV
